PT-141 (Bremelanotide) 10MG Research Vial - Melanocortin Receptor Agonist | Third-Party Tested
About PT-141 (Bremelanotide) 10MG Research Vial - Melanocortin Receptor Agonist | Third-Party Tested
PT-141, known systematically as Bremelanotide, is a synthetic cyclic heptapeptide and a nonselective agonist of the melanocortin receptor family. Structurally derived from the linear melanocortin agonist Melanotan II, it features an N-terminal acetylated norleucine (Nle) residue and a cyclic lactam bridge formed between an aspartate and lysine side chain, together with a D-phenylalanine substitution at position 4. These modifications produce a conformationally constrained scaffold (formula C₅₀H₆₈N₁₄O₁₀, molecular weight approximately 1,025.17 g/mol, CAS 189691-06-3, PubChem CID 9941379) with enhanced metabolic stability relative to its endogenous melanocortin analogs.
In the preclinical literature, PT-141 is used as a probe of melanocortin receptor signaling, with documented activity across the MC1R, MC3R, MC4R, and MC5R subtypes. Research interest centers on MC4R, which is highly expressed in hypothalamic regions including the medial preoptic area and has been implicated in central neuroendocrine and behavioral signaling in animal models. This item is supplied strictly as a reference material for in vitro and laboratory research use only and is not intended for human or veterinary use.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
PT-141 (Bremelanotide) 10MG Research Vial - Melanocortin Receptor Agonist | Third-Party Tested
M
PT-141, also known as Bremelanotide, is a synthetic research peptide associated with melanocortin receptor research. It is referenced in scientific literature examining receptor activity, peptide-receptor interactions, signaling pathways, and melanocortin-system pharmacology.
Each Helio Peptides PT-141 research vial contains 10MG of lyophilized research material.
Product Specifications
Compound: PT-141 / Bremelanotide
Research Format: Lyophilized powder
Content: 10MG per vial
Batch produced and batch tested
Third-party analytical testing
Identity and purity verification
Certificate of Analysis available
Manufactured in the USA
Intended exclusively for laboratory research
Research Use Only
This product is intended solely for laboratory research purposes. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Specifications
- MaterialPT-141 (Bremelanotide) 10MG Research Vial - Melanocortin Receptor Agonist | Third-Party Tested
- Also searched asPT141, PT 141, Bremelanotide
- Research AreaSexual Health Research
- Presentation—
- CAS Number189691-06-3
- Molecular FormulaC₅₀H₆₈N₁₄O₁₀
- Molecular Weight1,025.17 g/mol
- TypeSynthetic cyclic heptapeptide
- Receptor / TargetMelanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R)
- PubChem CID9941379 →
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Purity (HPLC)≥99%
- Identity (MS)Confirmed to specification
- TestingAccredited (ISO 17025) third-party laboratory
- DocumentationPer-batch COA →
In published preclinical and clinical research, Bremelanotide has been characterized as a high-affinity, nonselective melanocortin receptor agonist with predominant functional activity at MC1R and MC4R. Animal studies have reported that MC4R activation in the medial preoptic area of the hypothalamus is associated with downstream dopamine release, providing a mechanistic framework for its extensive study within central melanocortin signaling. Its cyclic lactam architecture and D-Phe substitution are consistently reported to improve resistance to enzymatic degradation relative to linear melanocortin peptides.
PT-141 was developed as a metabolite-derived analog of the linear melanocortin agonist Melanotan II, engineered into a cyclic heptapeptide to improve receptor engagement and metabolic stability. It became one of the most extensively studied melanocortin receptor agonists across preclinical and clinical research, and under the name Bremelanotide received FDA approval in June 2019 for a specific clinical indication in humans, following a large clinical development program.
- Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019.
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
- Clayton AH, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022;31(2):171-182.
- Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606.
- PubChem Compound Summary, CID 9941379, Bremelanotide. National Center for Biotechnology Information.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
Are these research materials third-party tested?
Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.
What purity are the materials?
Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.
Do you provide a Certificate of Analysis (COA)?
Yes. Per-batch COA documentation is provided and is traceable by lot number.
Where do you ship from?
Materials are shipped from the USA in discreet, protective packaging.
Are these products for human use?
No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.
More Sexual Health Research materials
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · 21+
